Bristol-Myers Squibb Company which can be found using ticker (BMY) now have 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between $64.00 and $33.10 and has a mean target at $53.53. Now with the previous closing price of $54.71 this would imply there is a potential downside of -2.2%. The day 50 moving average is $51.87 while the 200 day moving average is $48.07. The company has a market cap of 109.81B. Currently the stock stands at: $54.14 USD
The potential market cap would be $107,437,348,149 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $23.41 and a 6.07% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
